BioFluidica's next generation diagnostic platform, provides a non-invasive procedure that can be applied to many diseases where there is a need for improved diagnostics. The platform has been validated for six different cancer types, stroke, and infectious diseases. In the cancer field alone, there is a tremendous need to improve diagnostic capabilities. Globally, there are more than 14 million reported cancer cases per year. Each case being not just a number, but associated with a story of confusion, financial challenges, despair and loss. In the year 2030 it is projected that globally 11 million people will die of cancer. In the U.S. alone, there were more than 500,000 deaths and 1.66 million new cases reported in 2014. Direct cancer care costs in the U.S. have been estimated at $125 billion in 2010 and expected to grow to $200 billion by 2020.
Better cancer detection, and subsequent personalized treatment, precision medicine, are keys to improve patient treatment and outcomes. Detection of novel biomarkers, such as Circulating Tumor Cells, CTCs, are leading the way to improved diagnostics. The global market for CTC based diagnostics alone is estimated to reach almost $9 billion by 2018, with a compounded annual growth rate of 18.9% for 2013 – 2018*) . In order to improve the survival rate for many cancer diseases, the field of oncology needs better therapies and optimized personalized patient treatment. This will require the evolution of better technologies. BioFluidica is now delivering these new and improved technologies for the analysis of circulating markers, fullfilling the promise of a true liquid biopsy.
*) PHM153A – Reportlinker – Pathology, 2014